Pablo Corral on Why Early LDL-C Reduction Saves Lives
Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared on LinkedIn:
”Statins:
- The Power of Early Intervention and the Reality of the Legacy Effect
- The long arc of cardiovascular prevention continues to point in one direction: earlier LDL-C reduction delivers deeper, long-lasting protection. Two landmark analyses reinforce this principle with remarkable clarity.
The Scandinavian Simvastatin Survival Study (4S)—now revisited three decades after its publication—established that intensive LDL-C lowering not only reduces cardiovascular events but fundamentally alters long-term disease trajectories.
Its impact initiated a paradigm shift in dyslipidaemia management that persists today. (10.1016/S0140-6736(24)02089-0)
The ASCOT-Legacy 20-year follow-up extends this insight even further.
Despite convergence of lipid levels after trial completion, participants originally randomised to atorvastatin maintained significant long-term reductions in non-fatal myocardial infarction, fatal coronary heart disease, total coronary events, and cardiovascular mortality—demonstrating a true “legacy effect.”
Each 1 mmol/L lower in-trial LDL-C was associated with substantial long-term reductions in cardiovascular and all-cause mortality. (10.1136/heartjnl-2024-325104)
Key message:
- Statins do more than lower LDL-C today—they reduce the cumulative cholesterol burden that determines tomorrow’s risk.
- Starting earlier, treating consistently, and achieving lower LDL-C levels is not aggressive medicine—it is simply good medicine.
As the evidence mounts, the clinical imperative becomes harder to ignore:
Delay is costly.
Early, sustained lipid-lowering therapy saves lives.”
Stay updated with Hemostasis Today.
-
Dec 7, 2025, 17:01Abdul Mannan: How Do You Manage a Major Surgery When Blood Transfusion is Impossible?
-
Dec 7, 2025, 16:51Ahmed Bahi on Lina Merghani’s Critique of Early Withdrawal of Aspirin after PCI
-
Dec 7, 2025, 16:30Eloïse Laouenan Presents the Results of HEMOTHEPP-CHU Brest-GETBO Prospective Study
-
Dec 7, 2025, 16:21Jonathan Douxfils: Can We Estimate the VTE Risk of a Pill Before a Million Women Use It?
-
Dec 7, 2025, 15:53Paul Batty Congratulates Giulia Simini on Taking The Joint BSH-ASH Abstract Award
-
Dec 7, 2025, 15:35Federica Fogacci Presents The New ILEP Consensus Paper
-
Dec 7, 2025, 15:20Deep Molecular Modeling for Type 2A VWD from Omid Seidizadeh
-
Dec 6, 2025, 18:02ASH25 Day 1: Don’t Miss The Highlights
-
Dec 6, 2025, 15:44Atul Gupta on Where The Healthcare Innovation is Headed